Featured Research

from universities, journals, and other organizations

New compound dramatically reduces joint inflammation

Date:
December 10, 2013
Source:
Scripps Research Institute
Summary:
An experimental compound is capable of significantly reducing joint inflammation in animal models of rheumatoid arthritis.

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute (TSRI) has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

The study was published recently online ahead of print by the journal Arthritis & Rheumatism.

The study showed the compound, known as SR2211, blocked development of virtually all symptoms of rheumatoid arthritis in mice within the first eight to ten days of treatment. The mice also showed significantly reduced bone and cartilage erosion compared to animals that did not receive treatment.

The experimental compound targets the nuclear receptor RORγ, a key regulator of TH17 cells, one of a family of white blood cells that play a role in the immune system. Identified only a decade ago, TH17 cells have been implicated in numerous autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and lupus.

"This compound, and its precursors, showed the ability to block the release of specific inflammatory mediators from Th17 cells in culture, so we were confident that SR2211 would demonstrate good efficacy in rodent models of autoimmune disease," said biochemist Patrick R. Griffin, chair of the TSRI Department of Molecular Therapeutics. "Our newest study strongly supports the idea that by targeting the RORγ receptor, we can therapeutically repress inflammation and joint destruction associated with rheumatoid arthritis."

While several treatments are currently available for rheumatoid arthritis, Griffin noted their use is associated with the increased risk of infections and pneumonia. Since they have to be taken by injection, they are optimized for long, sustained immunosuppressive action, which is a disadvantage in managing opportunistic infections. An oral medication could be taken daily and stopped immediately to allow the drug to leave the body in the case of a potentially life-threatening infection.

"This study with SR2211 shows that repressing the activity of the RORγ receptor alone works to reduce joint erosion and inflammation," Griffin said. "It's an alternative mechanism of action that can provide doctors with additional treatment options for patients who do not respond well or cannot tolerate current therapies."

"We wanted to develop a compound with the potential to help treat patients suffering from a range of autoimmune diseases, including rheumatoid arthritis," said Staff Scientist Mi Ra Chang, the first author of the study and a member of the Griffin lab. "Compounds such as SR2211 work directly and specifically on at least two immune cell types directly involved in the pathogenesis of autoimmune disease."


Story Source:

The above story is based on materials provided by Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mi Ra Chang, Brent Lyda, Theodore M. Kamenecka, Patrick R. Griffin. Pharmacological repression of RORγ is therapeutic in the collagen-induced arthritis experimental model. Arthritis & Rheumatism, 2013; DOI: 10.1002/art.38272

Cite This Page:

Scripps Research Institute. "New compound dramatically reduces joint inflammation." ScienceDaily. ScienceDaily, 10 December 2013. <www.sciencedaily.com/releases/2013/12/131210152535.htm>.
Scripps Research Institute. (2013, December 10). New compound dramatically reduces joint inflammation. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2013/12/131210152535.htm
Scripps Research Institute. "New compound dramatically reduces joint inflammation." ScienceDaily. www.sciencedaily.com/releases/2013/12/131210152535.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins